AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.00 Decreased By ▼ -0.04 (-0.03%)
BOP 6.61 Decreased By ▼ -0.06 (-0.9%)
CNERGY 4.50 Decreased By ▼ -0.01 (-0.22%)
DCL 8.55 No Change ▼ 0.00 (0%)
DFML 41.78 Increased By ▲ 0.34 (0.82%)
DGKC 87.50 Increased By ▲ 0.65 (0.75%)
FCCL 32.59 Increased By ▲ 0.31 (0.96%)
FFBL 64.99 Increased By ▲ 0.19 (0.29%)
FFL 10.33 Increased By ▲ 0.08 (0.78%)
HUBC 109.37 Decreased By ▼ -0.20 (-0.18%)
HUMNL 14.65 Decreased By ▼ -0.03 (-0.2%)
KEL 5.09 Increased By ▲ 0.04 (0.79%)
KOSM 7.56 Increased By ▲ 0.10 (1.34%)
MLCF 41.40 Increased By ▲ 0.02 (0.05%)
NBP 59.61 Decreased By ▼ -0.80 (-1.32%)
OGDC 192.50 Increased By ▲ 2.40 (1.26%)
PAEL 28.20 Increased By ▲ 0.37 (1.33%)
PIBTL 7.79 Decreased By ▼ -0.04 (-0.51%)
PPL 150.99 Increased By ▲ 0.93 (0.62%)
PRL 26.85 Decreased By ▼ -0.03 (-0.11%)
PTC 16.03 Decreased By ▼ -0.04 (-0.25%)
SEARL 86.02 Increased By ▲ 0.02 (0.02%)
TELE 7.83 Increased By ▲ 0.12 (1.56%)
TOMCL 35.40 Decreased By ▼ -0.01 (-0.03%)
TPLP 8.24 Increased By ▲ 0.12 (1.48%)
TREET 16.38 Decreased By ▼ -0.03 (-0.18%)
TRG 53.19 Decreased By ▼ -0.10 (-0.19%)
UNITY 26.35 Increased By ▲ 0.19 (0.73%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
BR100 9,988 Increased By 104.4 (1.06%)
BR30 31,138 Increased By 537.6 (1.76%)
KSE100 94,161 Increased By 805.9 (0.86%)
KSE30 29,178 Increased By 246.6 (0.85%)

imageSWITZERLAND: Swiss drugmaker Novartis AG does not expect copycat versions of biotech drugs to play an important role in the healthcare system for another three to five years, its chief executive said on Monday.

Novartis' generics unit Sandoz is the No. 1 player in the field of copycat medicines, known as biosimilars because they are copies of biotech medicines made from living cells that cannot be replicated exactly.

Chief Executive Joe Jimenez said biosimilars generated about$500 million in sales for Novartis and were growing at a rate of about 20 percent per year.

"I think in two to three years you're not going to see a big difference," Jimenez told reporters gathered at Novartis' Basel headquarters for an event about the healthcare challenges of an aging population.

But he said he expected an "inflection point" following big biosimilar launches in 2017, 2018 and 2019, when many high-priced antibody drugs, which are among the pharmaceutical industry's biggest sellers, will lose patent protection.

"By the year 2020, which is just five years from now, you're going to see a big impact," Jimenez said. Several companies, including include Israel's Teva and Celltrion of South Korea, are racing to develop biosimilars ahead of looming patent expiries on blockbuster biotech medicines for treating cancer and autoimmune diseases.

As the global population ages, drugmakers such as Novartis are betting on a growing use of biosimilars as cash-strapped healthcare systems look for ways to cut spending.

But uncertainties over the US regulatory framework for biosimilars, plus high manufacturing costs and the need to run clinical trials to win approval, have caused delays.

Novartis' local rival Roche has repeatedly pushed back forecasts for when its expensive biotech cancer medicines will face generic competition.

Roche now expects to see biosimilar competition for its blood cancer drug MabThera, which lost patent protection at the end of last year in Europe, from 2016.

Comments

Comments are closed.